Clinical Trials · NCT03450109

A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate Cancer

CompletedPhase 1Gonadorelin (Approved)
Phase
Phase 1
Recruitment status
Completed
Sponsor
Luye Pharma Group Ltd.
Enrollment
19
Start date
Dec 2017
Locations
5 sites, United States
Primary endpoint
The bio-availability of goserelin in subjects receiving goserelin compared to Zoladex using Pharmacokinetic lab results
View Gonadorelin compound reference